Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Liquid Biopsy Market Size to Reach USD 9.50 Billion by 2030, Says The Brainy Insights

Published

on

Newark, Nov. 10, 2022 (GLOBE NEWSWIRE) — Liquid biopsy market size from USD 2.36 billion to USD 9.50 billion in 8 years: Increasing demand for advanced diagnosing equipment

Upcoming Opportunities

Brainy Insights estimates that the USD 2.36 billion in 2022 liquid biopsy market will reach USD 9.50 billion by 2030. In just eight years, the liquid biopsy is a minimally invasive diagnostic instrument helping not only in oncology applications but playing a rising role in applications containing infectious diseases and reproductive health. Further, liquid biopsy utilizes multiple techniques, including molecular and proteomic imaging. The quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS) describe the market’s significant technologies. Presently, marketed tests are mainly single-gene tests based on PCR. Still, the industry is moving towards a multi-cancer strategy utilizing NGS with various machine learning/artificial intelligence (ML/AI) approaches.

Get more insights from the 230-page market research report @ https://www.thebrainyinsights.com/enquiry/sample-request/13005

Key Insight of the Liquid Biopsy Market

North America to account for the largest market size during the forecast period

North America is expected to have the largest market share in the liquid biopsy market. Key factors favoring the growth of the liquid biopsy market in North America include greater investments and several biotechnology companies developing the tests. Further, the rising sensitivity of detecting techniques and assays, the increasing number of cancer cases, and the proliferation in healthcare expenditure are expected to drive market growth in this region.

The circulating tumor DNA (CTDNA) segment is expected to augment the liquid biopsy market during the forecast period.

The circulating tumor DNA (CTDNA) segment held the largest market share in 2022 and is expected to continue during the forecast period owing to the high frequency of cancer and strong demand for customized therapy.

The blood sample segment market size will be 0.99 billion in 2022

The blood sample segment is anticipated to dominate the market over the forecast period owing to the increasing awareness about regular health check-ups.

The hospitals and laboratories segment is anticipated to dominate the market by 48.12% in 2030

The hospitals and laboratories segment is anticipated to dominate the market in the forthcoming years, owing to the rapid technological advancements to enhance productivity and reduce costs.

The multi-gene-parallel analysis (NGS) segment accounted for the largest market share of 56.18% in 2022

The multi-gene-parallel analysis (NGS) segment held the largest share in the global liquid biopsy market, owing to the improved accessibility to NGSs in emerging economies and technological advancements. Also, the single gene analysis (PCR Microarrays) segment exhibited the highest CAGR during the forecast period owing to the rising demand for advanced diagnostics.

Advancement in market

In April 2021, Bio-Techne Company completed the acquisition of Asuragen, Inc.

In February 2021, Guardant Health Company announced the availability of Guardant Reveal, the first blood-only liquid biopsy test for detecting residual and recurrent illness from a simple blood draw. The first-of-its-kind commercial test enhances the management of early-stage colorectal cancer (CRC) patients by detecting circulating tumor DNA (ctDNA) in blood after surgery to recognize patients with residual disorder who may help most from adjuvant therapy.

In May 2020, the BRACAnalysis CDx test by Myriad Genetics Company was approved by Food and Drug Administration for utilization as a companion diagnostic by clinicians to detect metastatic castration-resistant prostate cancer in men. Lynparza is authorized for treating adult patients with somatic homologous recombination repair (HRR) gene-mutated or deleterious or suspected deleterious germline or metastatic castration-resistant prostate cancer (mCRPC) who have advanced following prior therapy with abiraterone or enzalutamide.

Custom Requirements can be requested for this report @ https://www.thebrainyinsights.com/enquiry/request-customization/13005

Market Dynamics

Driver: The increasing preference for minimally invasive procedures

The growing popularity of non-invasive techniques is driving private and public financing for research in liquid biopsy, which allows medical professionals to discover different aspects of a tumor via a patient’s blood sample. It facilitates medical professionals in understanding which therapies are appropriate for patients. Also, minimally invasive procedures are gaining surgical demand due to smaller incisions, quicker recovery, reduced scarring & pain, increased precision, and shorter hospital stays. In addition, the increasing launch of new products and a growing number of product approvals by several market players are also driving market growth. Further, liquid biopsies are an essential tool in clinical trials, helping pharma companies in patient choice, thus accelerating enrollment and lowering prices. This is particularly vital to drive targeted therapies.

Restraint: The stringent regulatory issues

The lack of specificity and sensitivity of liquid biopsy tests and unclear reimbursement & regulation scenario is the restraining factor of the market growth. Further, the stringent regulatory issues in different countries and the lack of skilled laborers hamper market growth. Additionally, the lack of standardization and the high cost of technology are impeding the market growth during the forecast period.

Opportunity: The growing significance of companion diagnostics

The growing significance of companion diagnostics is the opportunity factor for market growth. The companion diagnostics provide information critical for the safe and effective use of targeted treatments. Further, a food and drug administration-approved companion diagnostic test is utilized to determine which FDA-approved therapy options a patient may help from based on the genomic alterations within their tumor(s).

Challenges: The uncertain reimbursement and regulatory policies

The limited reimbursement (non-coverage for panel-based tests) limits the uptake of liquid biopsy testing. The NCD guidelines proved helpful in approving Foundation One’s genomic profiling assay but may work against other companies developing NGS-panel tests under the LDT scenario. Also, The NCD for Food and Drug Administration-approved NGS tests puts undue needs on companies manufacturing LDTs, limiting access to exhaustive liquid biopsy. CMS has carved away the enormous significance of liquid biopsy tests for screening and restricts coverage to specific conditions, like relapse monitoring, recurrence, relapse metastasis, or advanced Stage III and IV cancers.

Some of the major players operating in the liquid biopsy market are:

• CareDx Inc.
• Eurofins Scientific
• Exact Sciences Corporation
• Immucor, Inc.
• MDxHealth
• Menarini Silicon Biosystems
• GUARDANT HEALTH, INC
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Genomic Health
• Myriad Genetics, Inc.
• RainDance Technologies Inc.
• QIAGEN
• Exosome Diagnostics
• Biocept, Inc
• LungLife AI, Inc.
• Natera, Inc.
• Trovagene
• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories, Inc.

Key segments cover in the market:

By Biomarker Types:

• Circulating Tumor DNA (CTDNA)
• Circulating Tumor Cells (CTCs)
• Extracellular Vesicles (EVS)
• Others

By Sample:

• Urine Sample
• Blood Sample
• Others

By End-User:

• Academic and Research Centers
• Hospitals and Laboratories
• Others

By Technology:

• Single Gene Analysis (PCR Microarrays)
• Multi-gene-parallel Analysis (NGS)

By Region

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Have a question? Speak to Research Analyst @ https://www.thebrainyinsights.com/enquiry/speak-to-analyst/13005

About the report:

The market is analyzed based on value (USD Billion). All the segments have been analyzed worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report analyzes driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter’s five forces model, attractiveness analysis, Product analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients’ objectives of high-quality output within a short span of time. We provide both customized (clients’ specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients’ requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D
Head of Business Development
Phone: +1-315-215-1633
Email: [email protected] 
Web: http://www.thebrainyinsights.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending